Trial Profile
An observational, bicenter, retrospective, cohort study to evaluate the safety and efficacy of fingolimod versus natalizumab in patients with active relapsing-remitting mutiple sclerosis in a real life
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 21 Oct 2015 New trial record